Autolus Therapeutics PLC (NAS:AUTL)
$ 3.795 -0.045 (-1.17%) Market Cap: 1.01 Bil Enterprise Value: 314.39 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 55/100

Autolus Therapeutics PLC at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 05:45PM GMT
Release Date Price: $1.99 (+9.34%)
Noah I. Eisenberg
JPMorgan Chase & Co, Research Division - Research Analyst

Okay. With that, I guess we'll get started. Good morning, everyone. My name is Noah Eisenberg. I'm a biotech research associated with JPMorgan. It is my pleasure to introduce our next company -- presenting company, Autolus. Presenting on behalf of the company is CEO, Christian Itin. After the presentation, there will be a Q&A session. (Operator Instructions). So with that, I'll hand it over to Christian.

Christian Martin Itin
Autolus Therapeutics plc - CEO & Director

Thank you very much, and welcome, everybody. And first off, congratulations. You made it to Thursday at the JPMorgan conference. So that's an accomplishment in its own right. So great to see you all. And frankly, thanks for joining this late presentation and the schedule.

I'll be introducing you and walking you through where we are and where we stand with the -- our programs. We're developing CAR T therapies. And obviously, we're a listed company, and please look at our SEC filings for the risk

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot